Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study

The Lancet Oncology

Volumn 18, Issue 2, 2017, Pages 230-240

  Seymour, John F ^a,b,c   Ma, Shuo ^d   Brander, Danielle M ^e   Choi, Michael Y ^f   Barrientos, Jacqueline ^g   Davids, Matthew S ^h   Anderson, Mary Ann ^i,j   Beaven, Anne W ^e   Rosen, Steven T ^k   Tam, Constantine S ^a,b,c   Prine, Betty ^l   Agarwal, Suresh K ^l   Munasinghe, Wijith ^l   Zhu, Ming ^l   Lash, L Leanne ^l   Desai, Monali ^l   Cerri, Elisa ^l   Verdugo, Maria ^l   Kim, Su Young ^l   Humerickhouse, Rod A ^l   Gordon, Gary B ^l   Kipps, Thomas J ^f   Roberts, Andrew W ^b,c,i,j   more..

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b VICTORIAN COMPREHENSIVE CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NORTHWESTERN UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ ROYAL MELBOURNE HOSPITAL   (Australia)

^j WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^k CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^l ABBVIE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; VENETOCLAX; ANTINEOPLASTIC AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; DIARRHEA; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; LEUKEMIA RELAPSE; LEUKOPENIA; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTIC LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR GROWTH; UPPER RESPIRATORY TRACT INFECTION; CANCER GRADING; CLINICAL TRIAL; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; REMISSION; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; RITUXIMAB; SALVAGE THERAPY; SULFONAMIDES; SURVIVAL RATE;

EID: 85009505605     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(17)30012-8     Document Type: Article

References (23)

1. 1 Adams, JM, Cory, S, The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007), 1324–1337.
2. 2 Youle, RJ, Strasser, A, The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9 (2008), 47–59.
3. 3 Roberts, AW, Davids, MS, Pagel, JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med 374 (2016), 311–322.
4. 4 Roberts, AW, Seymour, JF, Brown, JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30 (2012), 488–496.
5. 5 Stilgenbauer, S, Eichhorst, B, Schetelig, J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17 (2016), 768–778.
6. 6 Wilson, WH, O'Connor, OA, Czuczman, MS, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11 (2010), 1149–1159.
7. 7 Souers, AJ, Leverson, JD, Boghaert, ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19 (2013), 202–208.
8. 8 Byrd, JC, Murphy, T, Howard, RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19 (2001), 2153–2164.
9. 9 O'Brien, SM, Kantarjian, H, Thomas, DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 19 (2001), 2165–2170.
10. 10 Hallek, M, Fischer, K, Fingerle-Rowson, G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376 (2010), 1164–1174.
11. 11 Robak, T, Dmoszynska, A, Solal-Céligny, P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 28 (2010), 1756–1765.
12. 12 Roberts, AW, Advani, RH, Kahl, BS, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol 170 (2015), 669–678.
13. 13 Kipps, TJ, Eradat, H, Grosicki, S, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 56 (2015), 2826–2833.
14. 14 Hallek, M, Cheson, BD, Catovsky, D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (2008), 5446–5456.
15. 15 O'Quigley, J, Pepe, M, Fisher, L, Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46 (1990), 33–48.
16. 16 Neuenschwander, B, Branson, M, Gsponer, T, Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 27 (2008), 2420–2439.
17. 17 Howard, SC, Jones, DP, Pui, CH, The tumor lysis syndrome. N Engl J Med 364 (2011), 1844–1854.
18. 18 Rawstron, AC, Villamor, N, Ritgen, M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21 (2007), 956–964.
19. 19 Kovacs, G, Robrecht, S, Fink, AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol 34 (2016), 3758–3765.
20. 20 Byrd, JC, Peterson, BL, Morrison, VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 (2003), 6–14.
21. 21 Wierda, W, O'Brien, S, Faderl, S, et al. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 106 (2006), 337–345.
22. 22 Badoux, XC, Keating, MJ, Wang, X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood 117 (2011), 3016–3024.
23. 23 Lamanna, N, Jurcic, JG, Noy, A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 27 (2009), 491–507.